COMMUNIQUÉS West-GlobeNewswire

Patient-Level Survival Analysis Demonstrates No Link Between Paclitaxel Dose and Mortality in Patients Treated with IN.PACT Admiral DCB

22/01/2019 - 13:01

Data Presented Today at LINC Reiterate Commitment to Patient Safety and Data Transparency DUBLIN and LEIPZIG, Germany - January 22, 2019 - Medtronic plc (NYSE:MDT) today announced new data shared on the IN.PACT(TM) [...]

Genmab Announces 2018 Net Sales Figures for DARZALEX® (Daratumumab)

22/01/2019 - 12:44

Company Announcement Net sales of DARZALEX in 2018 totaled USD 2,025 million Genmab receives royalties on worldwide sales from Janssen Biotech, Inc. Copenhagen, Denmark; January 22, 2019 – Genmab A/S (Nasdaq Copenhagen [...]

FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-801 for the treatment of PGM1 Deficiency

22/01/2019 - 12:30

ROCKVILLE, Md., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in [...]

MediWound Announces Positive Top-Line Results from Its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns

22/01/2019 - 12:30

Met Primary and All Secondary Endpoints with Statistically Significant Results Compared with Control Group Conference call with MediWound management and U.S. key opinion leader begins today, January 22, 2019 at 10:00 a. [...]

CorVel Announces Quarterly Earnings Release Webcast

22/01/2019 - 12:30

IRVINE, Calif., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Event: Quarterly Earnings Release Webcast Hosts: Gordon Clemons, Chairman Michael Combs, President and Chief Executive Officer Date: Tuesday, February 5, 2019 Time: 11: [...]

EMA Grants Orphan Drug Designation to TLC178 for the Treatment of Soft Tissue Sarcoma

22/01/2019 - 12:00

TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development [...]

Transactions in relation to share buyback program

22/01/2019 - 10:42

Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

Oasmia Pharmaceutical AB’s (publ, ”Oasmia”) decision to cancel the extraordinary general meeting on January 25, 2019

22/01/2019 - 10:00

The proposition on a new board of directors in Oasmia presented by Arwidsro Investment AB and Per Arwidsson (jointly “Arwidsro”) only a short period before the planned general meeting does not comply with Nasdaq [...]

Immunicum AB (publ) Announces Upcoming Investor Events in January

22/01/2019 - 08:31

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management [...]

ACACIA PHARMA ANNOUNCES SUPPORTIVE CARDIAC SAFETY DATA FOR BARHEMSYS™

22/01/2019 - 07:00

Cambridge, UK and Indianapolis, US – 22 January 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces results from its latest study of BARHEMSYS™ (intravenous amisulpride), its anti- [...]

Bone Therapeutics announces 2019 business outlook and reports year-end 2018 cash position

22/01/2019 - 07:00

Regulated information Phase IIA results with ALLOB in patients undergoing a spinal fusion procedure expected mid-2019 CTA submission planned in H2 2019 to start delayed-union fractures study with ALLOB Phase III study [...]

Bone Therapeutics annonce ses perspectives d’affaires pour 2019 et dresse son bilan de trésorerie

22/01/2019 - 07:00

Information réglementée Résultats de la phase IIA d’ALLOB pour les patients suivant une procédure de fusion vertébrale attendus pour la mi-2019 Demande d’autorisation d’essai clinique (CTA) pour l’étude d’ALLOB dans les [...]

Dr. Johan Luthman appointed EVP and Head of Research & Development in Lundbeck

22/01/2019 - 06:32

Valby, Denmark, 22 January 2019 - H. Lundbeck A/S (Lundbeck) today announced that Dr. Johan Luthman has been appointed Executive Vice President and Head of Research & Development in Lundbeck. Johan will assume his [...]

MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and other Neurodegenerative Diseases

22/01/2019 - 00:00

LA JOLLA, Calif., Jan. 21, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), [...]

Federal Judge Recognizes Free Speech for Cannabis Producer

21/01/2019 - 18:33

First-of-its-kind Federal Court ruling affirms medical cannabis speech cannot be restrained ALBUQUERQUE, N.M., Jan. 21, 2019 (GLOBE NEWSWIRE) -- For the first time in history, a Federal Court order has recognized the [...]

GENFIT: ANNOUNCES ITS FINANCIAL CALENDAR FOR 2019

21/01/2019 - 17:48

GENFIT: ANNOUNCES ITS FINANCIAL CALENDAR FOR 2019 Lille (France); Cambridge (Massachusetts, United States) - January 21, 2019 - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery [...]

GENFIT : ANNONCE SON CALENDRIER FINANCIER POUR 2019

21/01/2019 - 17:48

GENFIT : ANNONCE SON CALENDRIER FINANCIER POUR 2019 Lille (France) ; Cambridge (Massachusetts, États-Unis) - 21 janvier 2019 - GENFIT (Euronext : GNFT - ISIN : FR0004163111), société biopharmaceutique de phase avancée [...]

Ossur Hf : Transactions in relation to share buyback program

21/01/2019 - 17:00

Announcement no. 04/2019 21 January 2019 Transactions in relation to share buyback program On 9 October 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2018. The purpose of the share [...]

Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101 to Treat Leber Congenital Amaurosis 10 (LCA10)

21/01/2019 - 17:00

CAMBRIDGE, Mass., Jan. 21, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the journal Nature Medicine published the comprehensive, pre-clinical data [...]